TOP >>Main Part 2012 >>2-2 >>Dermatology
Dermatology |
Director AKIYAMA, Masashi (Professor) 6E |
All skin problems are within our field |
All the symptoms and changes on the skin fall within the domain of dermatologists. Even if such symptoms or changes are the result of systemic diseases, our department will treat them as long as they are on the skin. |
General outpatient clinic: Monday through Friday
Skin tumor outpatient clinic: Monday, Tuesday, Wednesday, and Friday
Collagen disorder outpatient clinic: Monday and Thursday
Outpatient clinic for ichthyosis and inherited dyskeratosis: Wednesday
Pigmentation disorder outpatient clinic: Monday and Thursday
Skin cancers (e.g., malignant melanoma, squamous cell carcinoma, basal cell carcinoma, Paget’s disease), benign skin tumors, collagen disorders (e.g., lupus erythematosus, dermatomyositis, scleroderma, Sjogren’s syndrome), genetic skin diseases (e.g., dyskeratosis, ichthyosis, epidermolysis bullosa and pigmentation disorder), atopic dermatitis, urticaria, and other skin diseases.
Diagnosis and treatment of skin cancers and benign tumors, skin surgery, skin cancer metastasis testing with sentinel lymph node biopsy, diagnosis and treatment of collagen disorders, genetic testing of a variety of genetic skin diseases, and detection of pathogenic factors of atopic dermatitis and filaggrin gene mutations.
We operated on 450 skin tumor cases per year. Of all the cases, skin cancer accounted for 180 (50 malignant melanoma, 42 squamous cell carcinoma and 44 basal cell carcinoma cases). The cumulative number of cases tested with sentinel lymph node biopsy is 200. Currently, the department has more than 200 outpatients suffering collagen disorders, such as lupus erythematosus, dermatomyositis and scleroderma. The cumulative number of genetic tests conducted on patients with severe genetic skin diseases is 300.
Skin tumor, skin surgery, collagen disorder, ichthyosis and inherited dyskeratosis, genetic pigmentation disorder and general dermatology.
Sentinel lymph node biopsy for the detection of lymph node metastases of malignant skin tumors (dye, RI and fluorescence methods in combination); tailor-made care of atopic dermatitis by detection of filaggrin gene mutations; research on the roles of various autoantibodies in the onset of collagen disorders; development of assay kits for diagnostic autoantibodies; and genetic testing and prenatal diagnosis for severe genetic skin diseases, such as ichthyosis, epidermolysis bullosa, pigmentation disorders and oculocutaneous albinism.